Accrol Group Holdings PLC

Continued progress in a challenging environment

Full year results 2021/22

6th September 2022







Disclaimer

2

The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested

This presentation is for information purposes only and no reliance may be placed upon it. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this presentation.

This presentation does not constitute or form part of any offer or invitation for sale or subscription of, or any solicitation of any offer to buy or subscribe for, any securities of Accrol Group Holdings plc. The making of this presentation does not constitute a recommendation regarding any such securities.

This presentation contains certain forward-looking statements. Any statement in this presentation that is not a statement of historical fact including, without limitation, those regarding Accrol Group Holding plc's future business, financial condition, financial performance, operations, prospects or developments is a forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "anticipates", "believes", "envisages", "estimates", "expects", "intends", "hopes", "may", "plans", "targets", "will", "would", "could" or "should" or a case, the negative of those, variations or comparable expressions. By their nature, forward-looking statements involve risk and uncertainty as they relate to events which occur in the future. No representation or warranty is made that any of these statements or forecasts will come to pass or that any forecast results will be achieved. Actual performance or results may differ materially from any future results, performance or achievement expressed or implied by these forward-looking statements. Factors which may give rise to such differences include (but are not limited to) changing business conditions, introduction of competing products by other companies, and changing economic, legal or regulatory conditions. New factors could emerge that could cause Accrol Group Holding plc's business not to develop as it expects. These and other factors could adversely affect the outcome and expectations. Accrol Group Holding plc does not intend to update any forward-looking statements contained in this presentation. The forward-looking statements contained in this presentation. Sector revisions to, any forward-looking statements in this presentation. No statements are made by the Directors of Accrol Group Holding plc and their beliefs and expectations. Accrol Group Holding statements in this presentation. No statement in the presentation is intended to be, or intended to be construed as, a profit forecast or profit estima





Our business

Our vision is to build a diversified business of size and scale

- Market Opportunity: the addressable market has grown significantly in the last 18 months and now totals £3bn – 33% share private label market
- Size & Scale: The Accrol manufacturing platform is well invested with capacity to +£300m revenue across multiple categories (at current pricing) – 19% share total market (up from 7% 2016)
- Diversification Growing new customers, expanding product range, adding new categories and additional routes to market – in growth across all products
- De-risking strength and breadth of customer partnerships, increasing internal efficiencies through fully automated manufacturing process, flexible and disciplined capital allocation – no one customer bigger than 20%



FY22 performance summary


Accelerating growth in private label and tertiary brand

- Revenue growth of 17% Volume up 7.5%
- Fully automated sites throughout +20% growth headroom from a fully invested platform
- Annualised £70m+ of cost increases recovered by Q4
- Continuing market share growth up to 19.5% (from 7% 2016)
- Resilient service to our customers despite significant supply chain challenges
- Accrol "branded product" sales run rate of 17.8% of total revenue from 9.7% in FY20




Market and revenue overview

UK Tissue Market Retail Sales Value (12m to April '22)



UK Tissue Market Retail Volume Q1'23 v FY22



- Overall market grew by 0.7% in value versus same 12m period LY
- Market share of 16.0% value (HY22: 15.3%, FY21: 15.9%), 19.5% volume share
- Toilet tissue market grew by +2.3%, kitchen towel declined (post pandemic)
- FY22 Brands represent 50% of the market; Private label 50% (April '22)

(Share now 54% private label 46% brands)

 Private label returning to growth as consumers increasingly seek value (Q1 23 – +10% growth)



Financial headlines

	FY22	FY21	Change	FY20
Revenue (£'m)	159.5	136.6	+17%	134.8
Gross margin	22.7%	27.7%	-5%	21.9%
Adjusted EBITDA (£'m) ¹	9.1	15.6	-42%	10.6
Adjusted PBT (£'m) ²	1.1	9.1	-88%	4.7
Net Debt (£'m) ³	27.5	14.6	-88%	17.9
Adjusted diluted EPS (pence)	0.3 p	2.7p	-2.4p	1.7p

¹ profit before finance costs, tax, depreciation, amortisation, adjusting items, and share based payments

² profit before tax, amortisation, adjusting items, and share based payments


³ excludes operating type leases recognised on the balance sheet in accordance with IFRS16



Revenue overview

Accrol Group - Revenue (£'m)

7



 \bigwedge we challenge \bigwedge we deliver \bigotimes we are honest \bigwedge

- A weak Q1 reflected ongoing impacts of COVID on discount retailers
- Strong recovery in H2 (+16%) as normal shopping behaviours returned (H1 Revenue £74m; H2 £86m)
- Price increases implemented in August '21, January '22 and May '22
- No customer losses and volumes strengthening in Q1 '23
- H1 Revenue £74m; H2 £86m +16% YoY


WE ADD VALUE

 Accrol: Tissue + 21% (market +2.3%); Kitchen Towel +16% (market -6.8%)



Cost and price increase

Accrol – Adjusted EBITDA Bridge (£'m)



- Q1 volume decline, but strong recovery in H2
- Significantly increased costs linked to pulp, energy, freight and distribution
- Pricing benefits impact after a lag price increase III impacting FY23
- Acquisitions now fully integrated

Input costs

- Pulp and paper prices climbed to record highs throughout the year
- Other materials (film and core board) increased significantly
- Global shipping issues could take another 6-12 months to resolve
- Haulage availability improved post H1 but fuel costs remain high

Price recovery

- Implemented price increases will add more than £70m to revenue post year end (£11m in FY22)
 - First price increase secured towards end of H1 £8m
 - Second price increase implemented in January '22
 £20m
 - Third price increase implemented in May '22 £45m
 - ✓ Fourth price increase planned from September 22




Cash flow and net debt

Accrol – Cashflow(£'m)

	FY22	FY21	Change
Adjusted EBITDA (£'m)	9.1	15.6	-6.5
Acquisition related items (£'m)	-0.8	-2.9	2.1
Separately disclosed items (£'m)	-2.0	-2.3	0.3
Working capital movement (£'m)	-4.6	6.6	-11.2
Other items	-0.3	-	-0.3
Operating Cashflows (£'m)	1.4	17.0	-15.6

Accrol – Adjusted Net Debt Bridge (£'m)



- Working capital expanded to manage supply constraints and rising costs
- Continued investment in manufacturing assets and product development with limited requirements going forward in the core business
- Net debt expanded to £27.5m (FY21:£14.6m)
- New Banking Facility increased headroom by a further 25%



Product development

We continue to develop our propriety branded product range

- Consolidated and re-designed our entire branded product offering
- Improved design, quality, and differentiation
- Clear focus on value and quality, offering at every tissue category
- Accrol branded sales up from 9.7% to 17.8% over the last 2 years and growing
- Have agreed and will launch a major global brand supply position in H1 FY23







Fastest growing 'brand' in cash and carry



Channel development

We continue to develop new sales channels

- Secured additional regions with major discounter and sole supply of private label with a leading grocer
- New customer wins include Spar and Sainsbury's with facial tissue
- New growth opportunities in sales channels such as cash & carry
- Independent channel specialist recruited and growing sales with wins at Unitas and Dhamecha
- Growing sales B2C and on Amazon
- Ocean brand run rate approaching £1m per annum and growing strongly



Our markets

Outperforming the markets



Operational highlights

Customer service improved and further operational efficiencies

- All sites have improved on output (pallets per week) over the last 12 months Blackburn +27%, Leyland +32%, Leicester +59%
- Following full automation across Blackburn, Leyland and Leicester resulted in a headcount reduction from 425 to 275 (Blackburn and Leyland L4L)
- Final stage of machine investment in Leyland (complete in H1 FY23)
- No lost time accidents at any site 33% reduction in all other minor accidents (e.g. cut finger)
- LTC and John Dale acquisitions fully integrated on time and on budget
- LTC capacity now fully utilised
 - John Dale revenue run rate increased from £2m to £6m (wet wipes only)





Sustainability highlights



Launch of our first Environmental, Social and Governance (ESG) Report

- Launch of the Group's first Environmental, Social and Governance Report in Sept '21
- Living Wage Accredited Member May 22
- Waste reduction program has delivered a further 0.5% reduction
- 10% reduction in logistics movements following move to 38mm paper cores
- Business continued to operate safely throughout the year with zero lost time accidents
- Absence levels 1.7% (UK average 2.2% ONS data FY21)
- Improvements in our ESG metrics are directly correlated to improvements in our core business metrics





Strategic review

- Strategic review, focused on how best to deliver value to all stakeholders, ongoing
- Considerable value within the Group, following the actions implemented over last 4 years
- Market opportunity substantial and growing Accrol well-invested/positioned relative to competition
- Mill plans fully developed and ready to be actioned when conditions permit
- Significant M&A opportunities when market support in place
- Long and mature partnerships in place in production and distribution
- Short term priority, however, on continued effective management of macro inflationary pressures and supply chain challenges
- Full update to be provided in early 2023





FY23 outlook

The growth opportunities for the Group remain very strong

- Full recovery of higher input costs, through prompt pricing actions pre-year end
- Tissue market fully recovered with growing share of private label versus brands Q1 54% vs 46%

 \swarrow we challenge \square we deliver \bigotimes we are honest \bigotimes we add value

- Q1 FY23 private label growth 10% Accrol growth 28%
- Accrol now accounts for over 30% of the growing private label market with this comes significant commercial strength
- On the supply side the business model allows for flexible purchasing by geography
- Discount retailers are growing strongly as consumers seek value and quality
- Strong start to the year & trading in line with forecasts in FY23 to date



Thank You

